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Abstract
Summary To determine the laboratory reproducibility of
urine N-telopeptide and serum bone-specific alkaline
phosphatase measurements, we sent identical specimens to
six US commercial labs over an 8-month period. Longitu-
dinal and within-run laboratory reproducibility varied
substantially. Efforts to improve the reproducibility of these
tests are needed.
Introduction We assessed the laboratory reproducibility of
urine N-telopeptide (NTX) and serum bone-specific alka-
line phosphatase (BAP).
Methods Serum and urine were collected from five
postmenopausal women, pooled, divided into identical
aliquots, and frozen. To evaluate longitudinal reproduc-
ibility, identical specimens were sent to six US commer-
cial labs on five dates over an 8-month period. To
evaluate within-run reproducibility, on the fifth date, each
lab was sent five identical specimens. Labs were unaware
of the investigation.
Results Longitudinal coefficients of variation (CVs) ranged
from 5.4% to 37.6% for NTX and from 3.1% to 23.6% for
BAP. Within-run CVs ranged from 1.5% to 17.2% for
NTX. Compared to the Osteomark NTX assay, the Vitros
ECi NTX assay had significantly higher longitudinal
reproducibility (mean CV 7.2% vs. 30.3%, p<0.0005) and
within-run reproducibility (mean CV 3.5% vs. 12.7%, p<
0.0005).
Conclusions Reproducibility of urine NTX and serum BAP
varies substantially across US labs.
Keywords Bone-specific alkaline phosphatase . Bone
turnover markers . Laboratory assay . Reproducibility .
Urine N-telopeptide
Introduction
Recent investigation has shown that biochemical markers of
bone turnover, both markers of bone resorption and markers
of bone formation, can confirm a biochemical response to
treatment of osteoporosis with antiresorptive agents [1], and
early changes in these markers can predict long-term
changes in bone mineral density [2]. Further, changes in
markers are associated with fracture risk [3–5].
Although these findings have secured a place for the use
of bone turnover markers in research trials, markers still are
not used frequently in clinical practice. Use in the diagnosis
and treatment of individual patients has largely been limited
by cost, by the data supporting marker significance, and by
variability, both pre-analytical and analytical. Pre-analytical
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variability includes biological variability, which comprises
that from circadian rhythms, diet, age, and gender [6], as
well as that due to sample handling and storage. Analytical
variability, in contrast, is that which originates from the
laboratory measurements themselves. While laboratory
assays are studied rigorously in standardized settings, data
are lacking about the reproducibility of bone turnover
marker measurements in actual clinical practice. The data
that do exist raise concerns: a European investigation
involving interlaboratory variation found that results for
most biochemical markers of bone turnover differed
markedly among laboratories [7]. In the USA, laboratory
standards are determined by the Clinical Laboratory
Improvement Amendments and assessed by proficiency-
testing providers such as the College of American Pathol-
ogists, but the results of cross-laboratory proficiency testing
are not routinely available to clinicians.
The evaluation of laboratory reproducibility in clinical
practice is especially important as laboratory assays evolve.
For some markers, manual enzyme-linked immunosorbant
assays (ELISAs) are being replaced by assays using the
same monoclonal antibodies but run on automated plat-
forms. Different laboratories may use distinct assays on
clinical specimens.
This study aimed to determine the laboratory reproduc-
ibility of two biochemical markers of bone turnover: urine
cross-linked N-telopeptide of type I collagen (NTX), a
marker of bone resorption, and serum bone-specific
alkaline phosphatase (BAP), a marker of bone formation.
Methods
Postmenopausal women older than 55 years of age were
recruited with advertising flyers posted around a large
academic medical center and in community businesses.
Volunteers were excluded if they were using current
pharmacologic therapy for osteoporosis, with relevant
therapy defined as estrogen, calcitonin, a selective estrogen
receptor modulator, a bisphosphonate, or teriparatide;
calcium and vitamin D supplements were permitted. All
volunteers provided verbal informed consent with the
assistance of an information sheet, given the minimal risks
involved in participation. The institutional review board of
the University of California, San Francisco approved the
study protocol prior to initiation of the study.
A pool of serum and a pool of urine were created from
specimens from five volunteers, in order to create samples
sufficiently large for the investigation and also in order to
minimize the interfering effects of medications or other
factors specific to a single volunteer. To create the pool of
serum, fasting morning blood from the participating women
was collected in eight gold-top serum separator tubes,
allowed to clot at room temperature for 30 min, and then
placed on ice, centrifuged, and separated. The pooled serum
was then stirred for 10 min in an ice water bath, divided
into 1.2 mL aliquots, and flash-frozen. To create the pool of
urine, fasting second-morning urine from the participating
women was collected, placed on ice, pooled, stirred for
10 min in an ice water bath, divided into 4 mL aliquots, and
flash-frozen. The serum and urine aliquots were then frozen
at −80°C.
Six US laboratories were selected for investigation, each
a recognized, high-volume commercial laboratory that
offers urine NTX and serum BAP testing: ARUP Labora-
tories (Salt Lake City, UT, USA), Esoterix Laboratory
Services (Calabasas Hills, CA, USA), Laboratory Corpora-
tion of America (LabCorp; Burlington, NC, USA), Mayo
Medical Laboratories (Rochester, MN, USA), Quest Diag-
nostics (Nichols Institute, San Juan Capistrano, CA, USA),
and Specialty Laboratories (Valencia, CA, USA). To
prevent bias, the laboratories were unaware of the investi-
gation; source-masked identifiers were used for all speci-
mens, and the specimens were sent by the authors'
institutional clinical laboratory as routine clinical specimens
ordered by clinicians would be sent. The laboratories were
paid in full via the standard contractual arrangements in
place with the authors' clinical laboratory. Each laboratory
was sent a serum and a urine specimen on five dates over
an 8-month period, in order to assess longitudinal (be-
tween-run) variability of the marker measurements. The
dates were 6 to 7 weeks apart, with the exception of those
sent to Specialty, for which the interval between the first
and second dates was 14 weeks. For all laboratories, on the
fifth date, five serum and five urine specimens were sent to
each laboratory in order to assess within-run variability of
the marker measurements.
Each of the six laboratories used one of two assays for
urine NTX measurements and one of two assays for serum
BAP measurements. For urine NTX, two laboratories
(LabCorp and Specialty) used the Osteomark assay (Inver-
ness Medical Innovations, Waltham, MA, USA), an ELISA
using a monoclonal antibody directed against a urinary pool
of collagen cross-links originally derived from a patient
with Paget's disease. Four laboratories (ARUP, Esoterix,
Mayo, and Quest) used the Vitros enhanced chemilumines-
cence (ECi) assay (Ortho-Clinical Diagnostics, Rochester,
NY, USA), a fully automated platform using the same
antigen. For serum BAP, one laboratory (Specialty) used
the Metra BAP enzyme immunoassay (Quidel, San Diego,
CA, USA), while five laboratories (ARUP, Quest, Esoterix,
Mayo, and LabCorp) used Access Ostase (Beckman
Coulter, Fullerton, CA, USA), another enzyme immunoas-
say. Of note, Metra BAP was formerly called Alkphase-B.
Access Ostase was formerly Hybritech Tandem-MP Ostase,
which itself was developed from the monoclonal antibody
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used for the Hybritech Tandem-R Ostase immunoradiomet-
ric assay.
The laboratories communicated the results by fax to the
authors' institutional clinical laboratory, as is done for
routine clinical specimens. Urine NTX values were reported
by all labs in whole numbers; BAP values were reported by
four of the labs to one tenth of a microgram per liter or unit
per liter but by Esoterix and Mayo as whole numbers.
Following standard practice, labs corrected urine NTX
values for dilution by urinary creatinine analysis and
reported results as NTX/creatinine ratios (to be referred to
simply as NTX in this paper).
Means, SDs, and coefficients of variation (CVs, defined
as mean/SD) with 95% confidence intervals (CIs) were
calculated [8]. A CV for within-run reproducibility for
BAP could not be computed for Esoterix because the
reported values were rounded to the nearest microgram per
liter and did not vary. Two sensitivity analyses were
performed: first, a uniform random variate on the interval
[−0.5, 0.5] was added to the BAP values reported by that
lab and by Mayo, which also rounded to the nearest
microgram per liter. Then, the perturbed results were
rounded to the nearest 0.1 μg/L, as reported by the other
labs. Second, CVs were computed after rounding reported
values from all six labs to the nearest microgram per liter
(or, for Metra, the nearest U/L). Assay-specific CVs were
computed for NTX and BAP measurements as the ratio of
the average within-lab SDs, obtained from a linear
regression of the measurement on laboratory, stratified
by assay type, to the overall average of the measurements
for that assay; CVs were compared across assays using the
methods of Feltz and Miller [9].
Results
The participating postmenopausal women were Caucasian
and ranged in age from 57 to 74 years (mean ± SD age 65±
6.3 years).
Longitudinal reproducibility was evaluated by sending
one specimen to each lab on each of five dates. For urine
NTX (Table 1, Fig. 1), CVs varied from 5.4% to 37.6%:
CVs were 5.4% (95% CI 3.2–15.5) for ARUP, 8.0% (CI
4.5–30.4) for Esoterix, 25.9% (CI 15.2–87.9) for LabCorp,
8.6% (CI 5.1–25.0) for Mayo, 6.6% (CI 3.9–19.1) for
Quest, and 37.6% (CI 21.6–168.0) for Specialty. Longitu-
dinal reproducibility was significantly lower for labs using
the Osteomark assay (CV 30.3%, CI 20.4–60.5) than for
those using the Vitros ECi assay (CV 7.2%, CI 5.5–10.6;
p<0.0005 for comparison between assays).
For BAP (Table 2, Fig. 2), longitudinal CVs ranged from
3.1% (CI 1.9–9.1) for Esoterix to 23.6% (CI 13.9–77.2) for
LabCorp. Analyses using perturbed data, done because
some labs' results were in whole numbers and some to one
tenth of a microgram per liter or unit per liter, gave similar
results. For example, the longitudinal CV for Esoterix,
which reported its results as whole numbers, became 4.5%
(CI 2.7–13.0) when the values were perturbed by random
variables before computations were performed, and the CV
Lab Assay Reference rangea Mean ± SD CV, % (95% CI)
ARUP Vitros ECi 26–124 35.8±1.9 5.4 (3.2–15.5)
Esoterix Vitros ECi 25–110 35.8±2.9 8.0 (4.5–30.4)
LabCorp Osteomark 5–65 74.2±19.3 25.9 (15.2–87.9)
Mayo Vitros ECi 19–63 35.0±3.0 8.6 (5.1–25.0)
Quest Vitros ECi 4–64 34.0±2.2 6.6 (3.9–19.1)
Specialty Osteomark 14–74 42.8±16.0 37.6 (21.6–168.0)
Vitros ECi (all) 35.1±2.5 7.2 (5.5–10.6)
Osteomark (all) 58.5±17.7 30.3 (20.4–60.5)
Table 1 Longitudinal reproduc-
ibility of urine NTX
Units for reference ranges,
means and SDs: nM BCE/mM
Cr
a Reference ranges, provided by
each laboratory, are for post-
menopausal women for ARUP
and Esoterix, premenopausal
women for Mayo and Quest,
and not specified for LabCorp
and Specialty
Fig. 1 Urine NTX measurements for the six laboratories. Send-out
rounds were of identical specimens and were 6 to 7 weeks apart, with
the exception of those sent to Specialty, for which the interval between
the first and second dates was 14 weeks
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for LabCorp, which reported its results to a tenth of a
microgram per liter, became 24.3% (CI 14.3–80.2) when
the values were rounded to whole numbers before compu-
tations were performed.
Within-run reproducibility was evaluated as each lab was
sent five identical specimens on one date. For urine NTX
(Table 3), CVs ranged from 1.5% (CI 0.9–4.3) for ARUP to
17.2% (CI 10.2–52.9) for Specialty. A comparison of
assays revealed a statistically significant difference, with
within-run CVs 12.7% (CI 8.7–23.5) for the Osteomark
assay and 3.5% (CI 2.6–5.1) for the Vitros ECi assay (p<
0.0005 for comparison between assays).
For BAP (Table 4), Esoterix produced five identical
measurements, and within-run CVs for the other labs
ranged from 2.2% (CI 1.3–6.3) for Quest to 15.5% (CI
9.2–47.1) for LabCorp. Analyses using perturbed data,
done because some labs' results were in whole numbers and
some to one tenth of a microgram per liter or unit per liter,
gave similar results. For example, the longitudinal CV for
Quest, which reported its results to a tenth of a microgram
per liter, became 3.8% (CI 2.3–11.0) when the values were
rounded to whole numbers before computations were
performed, and the CV for LabCorp, which also reported
its results to a tenth of a microgram per liter, became 15.1%
(CI 9.0–45.5). The CV for Mayo, which reported its results
as whole numbers, was 8.3% (CI 5.0–24.2) using the values
reported and became 9.3% (CI 5.3–27.3) when the values
were perturbed by random variables before computations
were performed. Of the five identical serum specimens sent
on one date to LabCorp, one was not processed, with the
reason cited “quantity not sufficient.”
In addition to means, SDs, and CVs for the NTX/
creatinine ratio (referred to simply as NTX in this paper),
computations were also done for NTX itself (uncorrected)
and for urine creatinine alone. CVs obtained for NTX itself
(uncorrected) appeared similar to those for the ratio (data
not shown).
Discussion
Despite their use in research trials, biochemical markers of
bone turnover still are not used frequently in clinical
practice, in part due to concerns about analytical variability.
In this masked study of identical specimens, the reproduc-
ibility of urine NTX and serum BAP was highly variable at
US commercial labs. On the one hand, several labs were
quite precise in their results longitudinally (between runs
separated in time) and within a given run: for example,
Esoterix produced five identical measurements for serum
BAP within one run. On the other hand, other labs were
imprecise: for example, LabCorp's CVs were greater than
Lab Assay Reference rangea Mean ± SD CV, % (95% CI)
ARUP Ostase 7.0–22.4 13.8±1.3 9.3 (5.6–27.3)
Esoterix Ostase ≤22.4 14.2±0.4 3.1 (1.9–9.1)
LabCorp Ostase 0.0–21.3 11.4±2.7 23.6 (13.9–77.2)
Mayo Ostase ≤22 14.4±0.9 6.2 (3.7–18.0)
Quest Ostase 5.6–29.0 14.4±1.5 10.4 (6.2–30.7)
Specialty Metra BAP 14.2–42.7 24.0±1.4 5.6 (3.4–16.3)
Ostase (all) 13.6±1.6 11.4 (8.9–16.0)
Metra BAP 24.0±1.4 5.6 (3.4–16.3)
Table 2 Longitudinal reproduc-
ibility of serum BAP
Units for reference ranges,
means and SDs: μg/L, except U/
L for Metra
a Reference ranges, provided by
each laboratory, are for post-
menopausal women for ARUP,
Mayo, and Esoterix, and not
specified for Quest, LabCorp,
and Specialty
Fig. 2 Serum BAP measurements for the six laboratories. Measure-
ments of BAP by the Metra assay, used by Specialty Labs, are in units
per liter, while measurements by the Ostase assay, used by the other
five laboratories, are in micrograms per liter. Send-out rounds were of
identical specimens and were 6 to 7 weeks apart
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20% for longitudinal specimens for both urine NTX and
serum BAP, with the lower ends of its 95% CIs greater than
13%, and its CV for within-run BAP measurements was
15.5% (CI 9.2–47.1).
Of important note is the difference in reproducibility of
urine NTX measurements when labs using the Osteomark
assay (Wampole Laboratories), an ELISA, are compared to
those using the Vitros ECi assay (Ortho-Clinical Diagnos-
tics), a fully automated chemiluminescence test. When
longitudinal and within-run reproducibility data were
compared in this study, the collective CVs for the Vitros
ECi assay were significantly lower than the collective CVs
for the Osteomark assay. This finding is consistent with the
findings of other studies comparing automated and manual
assays, such as an examination of urinary free deoxypyr-
idinoline assays that showed the precision of the automated
techniques studied was superior to that of the manual
immunoassays studied [10].
In fact, one interpretation of the significance of the
present study is not the overall inconsistent reproducibil-
ity of urine NTX and serum BAP but rather the marked
relative success of the newer, automated assays in
minimizing analytical variability. A limitation of the
present study is the small number of labs evaluated, as a
larger number using each type of assay would help
support this interpretation; the labs evaluated, though,
represent high-volume, well-known commercial labs
collectively responsible for a significant proportion of
the urine NTX and serum BAP assays conducted in the
USA.
Another limitation of the present study is the testing of a
single pooled sample for each marker, rather than the
testing of multiple pooled samples representing high,
normal, and low marker values. However, it is likely that
the reproducibility of measurements at the extremes of or
outside the normal range would show even greater
variability. As each lab determines its own reference ranges,
reference ranges varied, but this should not affect measure-
ment reproducibility. In addition, the assay used or the
reference range cited by each lab may have changed after
the completion of this study.
Clinical laboratories evaluate the quality of their results
through proficiency testing, which is required by the
Clinical Laboratory Improvement Amendments and per-
formed by organizations including the College of American
Pathologists, but survey results are not easily available to
practicing clinicians. These and other evaluations of marker
assays, such as one conducted as a part of a Centers for
Table 4 Within-run reproducibility of serum BAP
Lab Assay Reference rangea Mean ± SD CV, % (95% CI)
ARUP Ostase 7.0–22.4 15.6±0.6 3.8 (2.3–11.1)
Esoterix Ostase ≤22.4 14.0±0.0 0 (0–0)
LabCorpb Ostase 0.0–21.3 11.3±1.8 15.5 (9.2–47.1)
Mayo Ostase ≤22 13.2±1.1 8.3 (5.0–24.2)
Quest Ostase 5.6–29.0 14.2±0.3 2.2 (1.3–6.3)
Specialty Metra BAP 14.2–42.7 25.8±0.9 3.5 (2.1–10.1)
Ostase (all) 13.8±0.9 6.6 (5.2–9.3)
Metra BAP 25.8±0.9 3.5 (2.1–10.1)
Units for reference ranges, means and SDs: μg/L, except U/L for Metra
a Reference ranges, provided by each laboratory, are for postmenopausal women for ARUP, Mayo, and Esoterix, and not specified for Quest,
LabCorp, and Specialty
b Of the five identical serum specimens sent on one date to LabCorp, one was not processed, cited as “quantity not sufficient”
Lab Assay Reference rangea Mean ± SD CV, % (95% CI)
ARUP Vitros ECi 26–124 36.4±0.5 1.5 (0.9–4.3)
Esoterix Vitros ECi 25–110 34.0±1.4 4.2 (2.5–12.0)
LabCorp Osteomark 19–63 59.0±4.2 7.1 (4.2–20.6)
Mayo Vitros ECi 4–64 40.0±1.6 4.0 (2.4–11.4)
Quest Vitros ECi 5–65 34.0±1.2 3.6 (2.2–10.4)
Specialty Osteomark 14–74 52.8±9.1 17.2 (10.2–52.9)
Vitros ECi (all) 36.1±1.3 3.5 (2.6–5.1)
Osteomark (all) 55.9±7.1 12.7 (8.7–23.5)
Table 3 Within-run reproduc-
ibility of urine NTX
Units for reference ranges,
means and SDs: nM BCE/mM
Cr
a Reference ranges, provided by
each laboratory, are for post-
menopausal women for ARUP
and Esoterix, premenopausal
women for Quest and Mayo,
and not specified for LabCorp
and Specialty
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Disease Control study to develop a reference system to
standardize the measurements of bone resorption markers
pyridinium crosslinks pyridinoline and deoxypyridinoline
[11], invite labs to participate and announce the tested
specimens. While the results provide valuable information,
the concern exists that reproducibility may be at its best
during an announced test. The present study is important in
that the serum and urine specimens submitted to the six
high-volume US clinical labs investigated were processed
as routine clinical specimens ordered by clinicians would
be processed: the labs were unaware of the investigation,
fictional identifiers were used, and the specimens were sent
by the authors' institutional clinical laboratory, so the
specimens were indistinguishable from routine clinical
specimens. This element of the study's design was
considered extremely important, even though it prevented
the direct observation of potential factors that might have
explained some of the variability in lab reproducibility,
such as the handling of specimens by different labs. In the
past, some published studies comparing laboratory perfor-
mance have published data without naming the laboratories
[12, 13], but reaction in the literature has included the belief
that the laboratories should be identified [14]; the present
study provides laboratories' names in order that the results
and discussion generated be as useful as possible to
clinicians. The identification of laboratories by name is
similar to the identification of commercial assays by name
when such assays are compared, and this is not uncommon
in the literature [15–17].
Inconsistent reproducibility is a barrier to the use of
biochemical markers of bone turnover in clinical practice,
particularly if clinicians do not consistently use the same
assay and laboratory. The challenge of consistent use is
heightened by the fact that many institutional labs send
specimens out to higher-volume “send-out” labs (including
and especially those investigated here), and clinicians may
not be aware to which lab a specimen is being sent. Further,
and perhaps more importantly, information about the
particular assay used by a given lab is often difficult to
find: the type of assay (for example, “chemiluminescent
immunoassay”) is often listed in a lab's on-line catalog, but
none of the faxed reports of urine NTX results identified
whether the Vitros ECi or Osteomark assay had been used.
Of the faxed reports of serum BAP results, only the
Esoterix and LabCorp reports indicated the assay
employed, and even then, LabCorp referred to an outdated
form of the Ostase test.
The findings of the present study support the call for
urgent improvement in analytical precision for these two
biochemical markers of bone turnover. Laboratory perfor-
mance data should be made widely available to clinicians,
institutions, and payers, and proficiency testing and
standardized guidelines should be strengthened to improve
marker reproducibility at those labs currently performing
poorly.
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